Cingulate Completes Final FDA Study for CTx-1301 ADHD Treatment
On January 7, 2025, Cingulate Inc. (NASDAQ:CING) announced the successful completion of its final FDA-required study for CTx-1301 (dexmethylphenidate) aimed at treating Attention Deficit Hyperactivity Disorder (ADHD). This study, specifically a food effect study, represents a significant milestone in the development of the drug. The study involved the administration of a single 50mg dose of […]
More Stories
Collective Family Office LLC Has $1.06 Million Position in Vanguard Growth ETF (NYSEARCA:VUG)
Collective Family Office LLC cut its holdings in Vanguard Growth ETF (NYSEARCA:VUG – Free Report) by 2.5% during the fourth...
Collective Family Office LLC Purchases 43,583 Shares of Schwab U.S. Mid-Cap ETF (NYSEARCA:SCHM)
Collective Family Office LLC grew its position in Schwab U.S. Mid-Cap ETF (NYSEARCA:SCHM – Free Report) by 183.7% during the...
Collective Family Office LLC Has $7.90 Million Position in Dimensional National Municipal Bond ETF (NYSEARCA:DFNM)
Collective Family Office LLC grew its position in Dimensional National Municipal Bond ETF (NYSEARCA:DFNM – Free Report) by 5.0% during...
Collective Family Office LLC Reduces Stake in Schwab Long-Term U.S. Treasury ETF (NYSEARCA:SCHQ)
Collective Family Office LLC decreased its position in shares of Schwab Long-Term U.S. Treasury ETF (NYSEARCA:SCHQ – Free Report) by...
Collective Family Office LLC Has $4.19 Million Stock Position in Vanguard Mid-Cap Value ETF (NYSEARCA:VOE)
Collective Family Office LLC raised its stake in Vanguard Mid-Cap Value ETF (NYSEARCA:VOE – Free Report) by 15.1% during the...
Oriental Harbor Investment Fund Buys Shares of 442,942 Palantir Technologies Inc. (NASDAQ:PLTR)
Oriental Harbor Investment Fund purchased a new stake in Palantir Technologies Inc. (NASDAQ:PLTR – Free Report) in the 4th quarter,...